183 related articles for article (PubMed ID: 32980421)
21. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
22. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
23. Malignant melanoma of the conjunctiva.
Brownstein S
Cancer Control; 2004; 11(5):310-6. PubMed ID: 15377990
[TBL] [Abstract][Full Text] [Related]
24. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Swe T; Kim KB
Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
[TBL] [Abstract][Full Text] [Related]
26. Invasive conjunctival melanoma mimicking ocular surface squamous neoplasia: a case series.
Gallo B; Thaung C; Hay G; Arora AK; Cohen VM; Damato B; Sagoo MS
Br J Ophthalmol; 2021 Jun; 105(6):775-778. PubMed ID: 32675060
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and Management of Acral Lentiginous Melanoma.
Nakamura Y; Fujisawa Y
Curr Treat Options Oncol; 2018 Jun; 19(8):42. PubMed ID: 29951919
[TBL] [Abstract][Full Text] [Related]
28. Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.
Sa HS; Daniel C; Esmaeli B
J Ophthalmic Vis Res; 2022; 17(3):405-412. PubMed ID: 36160103
[TBL] [Abstract][Full Text] [Related]
29. [Case of corneally displaced malignant conjunctival melanoma].
Kabasawa S; Murayama K; Tsuchida T; Tanaka K; Arai E; Yoneya S
Nippon Ganka Gakkai Zasshi; 2007 Feb; 111(2):102-6. PubMed ID: 17338327
[TBL] [Abstract][Full Text] [Related]
30. [Malignant melanoma of the conjunctiva arising from precancerous melanosis, prognosis and treatment].
Desjardins L; Shields JA
J Fr Ophtalmol; 1983; 6(5):515-20. PubMed ID: 6630890
[TBL] [Abstract][Full Text] [Related]
31. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
32. Ocular melanoma: an overview of the current status.
Jovanovic P; Mihajlovic M; Djordjevic-Jocic J; Vlajkovic S; Cekic S; Stefanovic V
Int J Clin Exp Pathol; 2013; 6(7):1230-44. PubMed ID: 23826405
[TBL] [Abstract][Full Text] [Related]
33. Conjunctival melanoma: pitfalls and dilemmas in management.
Shildkrot Y; Wilson MW
Curr Opin Ophthalmol; 2010 Sep; 21(5):380-6. PubMed ID: 20531189
[TBL] [Abstract][Full Text] [Related]
34. Conjunctival Metastasis From Cutaneous Melanoma Demonstrating Complete Regression Following Checkpoint Inhibitor Therapy.
DeSimone JD; Lally SE; Shields CL
JAMA Ophthalmol; 2022 Jan; 140(1):e214786. PubMed ID: 35050376
[No Abstract] [Full Text] [Related]
35. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
36. NF1 mutations in conjunctival melanoma.
Scholz SL; Cosgarea I; Süßkind D; Murali R; Möller I; Reis H; Leonardelli S; Schilling B; Schimming T; Hadaschik E; Franklin C; Paschen A; Sucker A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Br J Cancer; 2018 May; 118(9):1243-1247. PubMed ID: 29559732
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
38. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations.
Demirci H; McCormick SA; Finger PT
Arch Ophthalmol; 2000 Jul; 118(7):885-91. PubMed ID: 10900099
[TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy for malignant melanoma].
Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
[TBL] [Abstract][Full Text] [Related]
40. Molecular Genetics of Conjunctival Melanoma and Prognostic Value of
van Poppelen NM; van Ipenburg JA; van den Bosch Q; Vaarwater J; Brands T; Eussen B; Magielsen F; Dubbink HJ; Paridaens D; Brosens E; Naus N; de Klein A; Kiliç E; Verdijk RM
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
